Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 01) diffuse large B-cell lymphoma

Enrico Derenzini, Vittorio Stefoni, Cinzia Pellegrini, Maria Paola Fina, Alessandro Broccoli, Filippo Venturini, Letizia Gandolfi, Stefano A. Pileri, Maurizio Martelli, Maria Concetta Petti, Alessio Perrotti, Amalia De Renzo, Francesco Zaja, Michele Baccarani, Pier Luigi Zinzani

Research output: Contribution to journalArticlepeer-review

Abstract

Young patients (aged 1860 years) with good-prognosis diffuse large B-cell lymphoma (DLBCL) [0 and 1 risk factor according to age-adjusted international prognostic index (aa-IPI)] are distinguished from patients with poor-prognosis. Six cycles of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) in combination with rituximab achieved best results in young patients with low-risk DLBCL. We retrospectively analyzed the data of 82 patients (1860 years) with untreated aa-IPI 01 DLBCL, from six Italian institutions, who underwent, between January 2002 and January 2007, rituximab-cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone (R-MACOP-B) therapy followed, in patients with bulky presentation, by 3036 Gy involved-field radiation therapy (34 patients). An overall response rate was noted in 77 out of 82 (94) patients (75 patients had a complete response (91), 2 patients had a partial response). With a median follow-up of 46 months, 7-year progression-free and overall survival were estimated to be 91 and 94, respectively. R-MACOP-B regimen followed by involved-field radiation on bulky presentation is safe and very effective in the treatment of young patients with low-risk DLBCL.

Original languageEnglish
Pages (from-to)1824-1829
Number of pages6
JournalLeukemia and Lymphoma
Volume50
Issue number11
DOIs
Publication statusPublished - Nov 2009

Keywords

  • Chemotherapy
  • Diffuse large B-cell lymphoma
  • IPI score
  • MACOP-B
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 01) diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this